Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. | ||||
Medical Journal of Viral Hepatitis | ||||
Article 4, Volume 5.3, Issue 3, September 2021, Page 22-26 PDF (158.29 K) | ||||
Document Type: Original article | ||||
DOI: 10.21608/mjvh.2021.193441 | ||||
View on SCiNiTO | ||||
Authors | ||||
Folly Anyovi 1, 2; Akomola k. Sabi3, 4; Yoan y. Amekoudi4; Mawufemo C. Tsevi4; Reham Soliman5, 6; Pardessus Charles7; Simplice Karou8; Jacques Simpore1, 2; Shiha Gamal9, 10 | ||||
1Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR-SVT, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso. | ||||
2Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364 Ouagadougou 01, Burkina Faso. | ||||
3Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo. | ||||
4CHU Sylvanus Olympio, Service de Néphrologie-Hemodialyse, | ||||
5Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt | ||||
6Tropical Medicine Department, Faculty of Medicine, Port Said University, Egypt | ||||
7Faculté des sciences de la Santé, Université de Lomé. | ||||
8Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo | ||||
9Internal Medicine dept., Mansoura Univ., Egypt | ||||
10Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt. | ||||
Abstract | ||||
Background: The prevalence of hepatitis B surface antigen (HBsAg) and anti-HCV infection (anti-HCV) among hemodialysis patients (HD) varies from country to country and from one center to another. This cross-sectional study was conducted to investigate seroprevalence and associated risk factors for HBsAg and anti-HCV markers among hemodialysis patients in S.O. CHU in Lomé. Materials and methods: Structured questionnaires were used to obtain socio-demographic data and sera were tested for HBsAg and anti-HCV among End Stage Renal Disease (ESRD) patients undergoing hemodialysis in S.O. CHU in Lomé. Results: Out of 75 patients enrolled in the study, HBsAg and anti-HCV were detected in 6 (8%) and 11 (14.7%) patients respectively. Anti-HCV and HBsAg seropositivity were not associated with the hemodialysis session (p = 0.88) and (p = 0.91) respectively. Furthermore, Univariate analysis showed that, sex, tatoo before dialysis and a history of surgery were not a significant risk factors for HBsAg and HCV seropositivity. The follow-up of the ALT in the both patients (HCV and HBsAg) showed very high significant variation (p = 0.000) and (p = 0.02) respectively. Conclusion: Prevalence of HBsAg and anti-HCV in hemodialysis patients seems low in Lomé. It is recommended to check the patients for HBsAg and anti-HCV before admission to the centers. | ||||
Keywords | ||||
Seroepidemiology; HBV; HCV; hemodialysis; Togo | ||||
Statistics Article View: 182 PDF Download: 322 |
||||